239 reports of this reaction
1.4% of all BISMUTH SUBSALICYLATE reports
#19 most reported adverse reaction
OSTEOPOROSIS is the #19 most commonly reported adverse reaction for BISMUTH SUBSALICYLATE, manufactured by Lil' Drug Store Products, Inc.. There are 239 FDA adverse event reports linking BISMUTH SUBSALICYLATE to OSTEOPOROSIS. This represents approximately 1.4% of all 17,164 adverse event reports for this drug.
Patients taking BISMUTH SUBSALICYLATE who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPOROSIS is a less commonly reported adverse event for BISMUTH SUBSALICYLATE, but still significant enough to appear in the safety profile.
In addition to osteoporosis, the following adverse reactions have been reported for BISMUTH SUBSALICYLATE:
The following drugs have also been linked to osteoporosis in FDA adverse event reports:
OSTEOPOROSIS has been reported as an adverse event in 239 FDA reports for BISMUTH SUBSALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPOROSIS accounts for approximately 1.4% of all adverse event reports for BISMUTH SUBSALICYLATE, making it a notable side effect.
If you experience osteoporosis while taking BISMUTH SUBSALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.